Cipla
| Cipla | |
| Formerly | Chemical Industrial & Pharmaceutical Laboratories Ltd. (1935–1984) |
| Company type | Public |
| BSE: 500087 NSE: CIPLA NSE NIFTY 50 constituent | |
| ISIN | INE059A01026 |
| Industry | Pharmaceuticals |
| Founded | 1935 |
| Founder | Khwaja Abdul Hamied |
| Headquarters | Mumbai, Maharashtra, India |
Area served | Worldwide |
Key people |
|
| Products | |
| Revenue | ₹27,548 crore (US$3.3 billion) (2025) |
| ₹7,128 crore (US$840 million) (2025) | |
| ₹5,273 crore (US$620 million) (2025) | |
| Total assets | ₹37,387 crore (US$4.4 billion) (2025) |
| Total equity | ₹31,289 crore (US$3.7 billion) (2025) |
Number of employees | 27,764 (March 2024) |
| Subsidiaries | Invagen Pharmaceuticals |
| Website | www.cipla.com |
| Footnotes / references Financials as of 31 March 2025. | |
Cipla Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Cipla primarily focuses on developing medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, paediatric and various other medical conditions. Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third-largest drug producer in India.